Cannabidiol: State of the art and new challenges for therapeutic applications

S Pisanti, AM Malfitano, E Ciaglia, A Lamberti… - Pharmacology & …, 2017 - Elsevier
Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …

Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age

JA Crippa, FS Guimarães, AC Campos… - Frontiers in …, 2018 - frontiersin.org
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a
compound that does not produce the typical subjective effects of marijuana. Objectives: The …

Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and …

EP Baron - Headache: The Journal of Head and Face Pain, 2018 - Wiley Online Library
Background Comprehensive literature reviews of historical perspectives and evidence
supporting cannabis/cannabinoids in the treatment of pain, including migraine and …

Cannabidiol for neurodegenerative disorders: A comprehensive review

S Bhunia, N Kolishetti, AY Arias, A Vashist… - Frontiers in …, 2022 - frontiersin.org
Despite the significant advances in neurology, the cure for neurodegenerative conditions
remains a formidable task to date. Among various factors arising from the complex etiology …

From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology

A Ligresti, L De Petrocellis… - Physiological …, 2016 - journals.physiology.org
Apart from having been used and misused for at least four millennia for, among others,
recreational and medicinal purposes, the cannabis plant and its most peculiar chemical …

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation

S Burstein - Bioorganic & medicinal chemistry, 2015 - Elsevier
First isolated from Cannabis in 1940 by Roger Adams, the structure of CBD was not
completely elucidated until 1963. Subsequent studies resulted in the pronouncement that …

Cannabidiol, neuroprotection and neuropsychiatric disorders

AC Campos, MV Fogaça, AB Sonego… - Pharmacological …, 2016 - Elsevier
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis
sativa. It has possible therapeutic effects over a broad range of neuropsychiatric disorders …

Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects

EB Russo - British journal of pharmacology, 2011 - Wiley Online Library
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964,
when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic …

Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials

S Silvestro, S Mammana, E Cavalli, P Bramanti… - Molecules, 2019 - mdpi.com
Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from
Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest …

Cannabidiol as a therapeutic target: evidence of its neuroprotective and neuromodulatory function in Parkinson's disease

F Patricio, AA Morales-Andrade… - Frontiers in …, 2020 - frontiersin.org
The phytocannabinoids of Cannabis sativa L. have, since ancient times, been proposed as a
pharmacological alternative for treating various central nervous system (CNS) disorders …